Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17 - 2'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- 3Make your choice for a definitive Christmas place to get-away!
- 4Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- 5The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- 10 Moves toward Start Your Own Effective Business
- Great DSLR Cameras for Photography Devotees
- Wedding trip Objections in the US
- Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- Artemis 2 moon astronauts will try to recreate Apollo 8's historic 'Earthrise' photo during April 6 flyby
- The Best 10 Innovation Advancements of the Year
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- Kristin Cavallari was the teen queen bee of 'Laguna Beach.' Now she's a 'cringey' mom.
- Experience Arranging: Planning for Epic Excursions
